Liver Lineup: Advances in Portal Hypertension and Cirrhosis Management

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down several of the most consequential hepatology developments of 2025, focusing on practical advances in the management of patients with advanced liver disease. From renal protection in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis to long-debated questions around albumin dosing and emerging tools for monitoring hepatic encephalopathy at home, the discussion centers on how new data may begin to shift everyday clinical decision-making.

Key episode timestamps:
0:00:00 – Dapagliflozin in MASLD cirrhosis with ascites
0:04:41 – Clinical perspective on dapagliflozin & management strategy
0:06:37 – Albumin for hyponatremia in cirrhosis
0:12:28 – How clinicians currently use albumin in practice
0:18:43 – Low‑dose vs conventional‑dose albumin in high‑risk SBP 
0:25:03 – Beacon device: at‑home critical flicker frequency for HE
0:27:47 – Future of at‑home HE monitoring & closing remarks